

参 考 文 献

- Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. *Annu Rev Immunol*, 2003, 21:685 - 711.
- Okada N, Mori N, Koretomo R, et al. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. *Gene Ther*, 2005, 12:129 - 139.
- Lu L, Lee WC, Takayama T, et al. Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta, and CTLA4lg). *J Leukoc Biol*, 1999, 66:293 - 296.
- Dietz AB, Bulur PA, Brown CA, et al. Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression. *Gene Ther*, 2001, 8:419 - 423.
- 王永权,彭毅志,王强,等. 脂质体介导的基因转染对未成熟树突状细胞成熟特性的影响. *中华烧伤杂志*, 2006, 22:203 - 206.
- Larcher C, Nguyen VA, Fuhapter C, et al. Human herpesvirus-8 infection of umbilical cord-blood-derived CD34⁺ stem cells enhances the immunostimulatory function of their dendritic cell progeny. *Exp Dermatol*, 2005, 14:41 - 49.
- 王强,彭毅志. 小鼠骨髓未成熟树突状细胞体外扩增及鉴定. *中华烧伤杂志*, 2003, 19:332 - 335.
- Commeren DL, Van Soest PL, Karimi K, et al. Paradoxical effects of interleukin-10 on the maturation of murine myeloid dendritic cells. *Immunology*, 2003, 110:188 - 196.
- Olszewski WL. Tolerogenic properties of dendritic cells in allografting. *Ann Transplant*, 2003, 8:5 - 9.
- Raimondi G, Thomson AW. Dendritic cells, tolerance and therapy of organ allograft rejection. *Contrib Nephrol*, 2005, 146:105 - 120.
- Rouard H, Leon A, Klonjowski B, et al. Adenoviral transduction of human clinical grade immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity. *J Immunol Methods*, 2000, 241:69 - 81.
- Tan PH, Beutelspacher SC, Xue SA, et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. *Blood*, 2005, 105:3824 - 3832.
- Bhattacharya S, Sen P, Wallet M, et al. Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkkappaB kinase activity. *Blood*, 2004, 104:1100 - 1109.
- Copland MJ, Baird MA, Rades T, et al. Liposomal delivery of antigen to human dendritic cells. *Vaccine*, 2003, 21:883 - 890.

(收稿日期:2006-02-20)

(本文编辑:王旭)

· 病例报告 ·

治疗二氯甲烷烧伤一例

赵耀华 徐涛

患者男,22岁,工作时被热二氯甲烷(温度约80℃)泄漏喷溅于双眼、右上肢等部位,伤后2h后用水冲洗创面,并在邻近诊所输液(药名不详),因患者呼吸困难,伤后10h收入笔者单位。查体:患者睑结膜充血水肿,睁眼困难,咽腔充血,声音嘶哑,自感胸闷,有轻度“三凹征”,双肺可闻及干性啰音,烧伤创面主要分布于右上肢及背部。白细胞计数(WBC) $18.6 \times 10^9/L$ 、红细胞计数(RBC) $6.86 \times 10^{12}/L$ 、中性粒细胞(GR) 0.95、淋巴细胞 0.5、血钾 4.01 mmol/L、血钠 145 mmol/L、血氯 113 mmol/L、血钙 2.3 mmol/L、二氧化碳结合力 34 mmol/L、尿素氮(BUN) 6.40 mmol/L。血气分析:pH 7.43,氧分压 80 mm Hg(1 mm Hg = 0.133 kPa),二氧化碳分压 34 mm Hg,剩余碱 -4 mmol/L。胸部X线片显示:右肺炎。诊断:(1)二氯甲烷烧伤,其中Ⅰ度 6%、浅Ⅱ度 3% TBSA。(2)双眼烧伤。(3)轻度吸入性损伤合并肺炎。

入院后立即静脉注射地塞米松 20 mg,1次/d,持续 5 d;静脉滴注能量合剂及头孢哌酮/舒巴坦 2.0 g,2次/d;成纤维细胞生长因子(贝复舒,珠海亿胜生物制药有限公司)滴眼,2h/次,红霉素眼膏涂眼 1次/天;3d内给予持续吸氧,流量为 4 L/min;创面清创后用磺胺嘧啶银锌膏包扎,隔日换药 1次,直至创面愈合。伤后第2天,患者背部、右上臂创面出现大小不等的水疱,证实为深Ⅱ度创面,面积为 8%、浅Ⅱ度 1% TBSA。声音嘶哑加重,双肺可闻及湿性啰音,创面肿胀较甚且渗出多。伤后第5天,病情明显好转,偶见稀薄痰

液,双眼视物较以前清晰,水肿逐渐消退,巩膜充血减轻,创面渗出减少。WBC $12.1 \times 10^9/L$ 、血小板计数 $210 \times 10^9/L$ 、RBC $5.56 \times 10^{12}/L$ 、GR 0.76、血钾 4.55 mmol/L、血钠 138 mmol/L、血氯 108 mmol/L、BUN 3.75 mmol/L。伤后第10天,双肺听诊无湿性啰音,偶可闻及干鸣音,睑结膜充血消失,视物清晰。伤后18d患者痊愈出院。

讨论 二氯甲烷为无色透明易挥发液体,属低毒类,其蒸气麻醉性强,大量吸入会引起急性中毒,出现鼻腔疼痛、头痛、呕吐等症状。其与皮肤接触时易引起皮炎和烧伤,由于沸点(39.75℃)低,蒸气比空气重,遇明火或与灼热物体接触时生成剧毒光气,吸入浓度为 $90.5 g/m^3$ 达 40 min 便可致死^[1]。本病例入院后第2天创面由Ⅰ度演变为深Ⅱ度,说明二氯甲烷液体具有刺激性和腐蚀性,如伤后立即用流动水冲洗创面有助于减轻伤情。

目前尚无二氯甲烷的有效解毒剂。因此,接诊此类患者时应详细询问病史、观察致伤物质性质,有条件时尽快现场采样进行分析;严密观察吸入性损伤及中毒情况,必要时行预防性气管切开,以免酿成不良后果。从患者吸入性损伤情况看,二氯甲烷的挥发性对呼吸道刺激性较强,应引起重视。

参 考 文 献

- 程能林,主编. 溶剂手册. 北京:化工工业出版社,2002. 195 - 197.

(收稿日期:2006-05-09)

(本文编辑:莫愚)